<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35571739</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1741-427X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>2022</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
          <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Luteolin Induced Hippocampal Neuronal Pyroptosis Inhibition by Regulation of miR-124-3p/TNF-<i>α</i>/TRAF6 Axis in Mice Affected by Breast-Cancer-Related Depression.</ArticleTitle>
        <Pagination>
          <StartPage>2715325</StartPage>
          <MedlinePgn>2715325</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2715325</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/2715325</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Breast-cancer-related depression (BCRD) is associated with an increased mortality rate among breast cancer (BC) survivors. Luteolin has many pharmacological effects, particularly in the treatment of BC. In this study, we aimed to explore the anti-BCRD activity of luteolin and its underlying functional mechanism.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A BCRD mouse model was induced by injecting 4T1 cells and corticosterone (COR). Behavioral test, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, Nissl staining, immunofluorescence, reverse-transcription quantitative PCR (RT-qPCR), and western blotting were used to study the effect of luteolin in mice with BCRD in vivo. A COR-induced neuron injury model was established in HT-22 cells in vitro. The role of miR-124-3p in the anti-BCRD effects of luteolin was studied using a miR-124-3p inhibitor.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Luteolin significantly reduced the size and weight of the tumor, increased the mice entry frequency in the symmetrical sector, and reduced the duration of immobility in the tail suspension and forced swimming tests of mice affected by BCRD. Simultaneously, apoptosis of hippocampal neurons was inhibited, and the number of Nissl bodies increased with luteolin treatment. In addition, luteolin resulted in the upregulation of miR-124-3p expression in the hippocampus and downregulated the expression of tumor necrosis factor-<i>α</i> (TNF-<i>α</i>) and TNF receptor-associated factor 6 (TRAF6), as well as lowered the phosphorylation levels of nuclear factor-kappa B (NF-<i>κ</i>B) and IkappaB (I<i>κ</i>B). Luteolin also inhibited pyroptosis of hippocampal neurons in mice affected by BCRD, as revealed by the low protein levels of NOD-like receptor protein 3 (NLRP3), caspase-1, gasdermin D-N (GSDMD-N), interleukin (IL)-1<i>β</i>, and IL-18. However, the miR-124-3p inhibitor significantly reversed the therapeutic effect of luteolin on COR-induced HT-22 cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our study demonstrated that the anti-BCRD function of luteolin was mediated by regulating the miR-124-3p/TNF-<i>α</i>/TRAF6-related pathway and inhibiting neuronal cell pyroptosis and subsequent inflammation. Therefore, luteolin may be a potential drug candidate in the treatments of BCRD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Qing Zhu et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Pan</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Yuanshan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-6774-2522</Identifier>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zhuo</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuhong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-1411-2201</Identifier>
            <AffiliationInfo>
              <Affiliation>Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Minghui</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1025-6216</Identifier>
            <AffiliationInfo>
              <Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
        <NlmUniqueID>101215021</NlmUniqueID>
        <ISSNLinking>1741-427X</ISSNLinking>
      </MedlineJournalInfo>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>4</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35571739</ArticleId>
        <ArticleId IdType="pmc">PMC9106465</ArticleId>
        <ArticleId IdType="doi">10.1155/2022/2715325</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Africander D., Storbeck K.-H. Steroid metabolism in breast cancer: where are we and what are we missing? 
Molecular and Cellular Endocrinology
. 2018;466:86–97. doi: 10.1016/j.mce.2017.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2017.05.016</ArticleId>
            <ArticleId IdType="pubmed">28527781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okamura M., Yamawaki S., Akechi T., Taniguchi K., Uchitomi Y. Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life. 
Japanese Journal of Clinical Oncology
. 2005;35(6):302–309. doi: 10.1093/jjco/hyi097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jjco/hyi097</ArticleId>
            <ArticleId IdType="pubmed">15961434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shim E.-J., Lee J. W., Cho J., et al.  Association of depression and anxiety disorder with the risk of mortality in breast cancer: a national health insurance service study in Korea. 
Breast Cancer Research and Treatment
. 2020;179(2):491–498. doi: 10.1007/s10549-019-05479-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-019-05479-3</ArticleId>
            <ArticleId IdType="pubmed">31673880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich M., Lesur A., Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. 
Breast Cancer Research and Treatment
. 2008;110(1):9–17. doi: 10.1007/s10549-007-9706-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-007-9706-5</ArticleId>
            <ArticleId IdType="pubmed">17674188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casaril A. M., Domingues M., Bampi S. R., et al.  The antioxidant and immunomodulatory compound 3-[(4-chlorophenyl)selanyl]-1-methyl-1H-indole attenuates depression-like behavior and cognitive impairment developed in a mouse model of breast tumor. 
Brain, Behavior, and Immunity
. 2020;84:229–241. doi: 10.1016/j.bbi.2019.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2019.12.005</ArticleId>
            <ArticleId IdType="pubmed">31837417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.-Y., Kim J.-M., Kim S.-W., et al.  Associations between plasma cytokines and depressive mood in patients with breast cancer. 
International Journal of Psychiatry in Medicine
. 2012;43(1):1–17. doi: 10.2190/pm.43.1.a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2190/pm.43.1.a</ArticleId>
            <ArticleId IdType="pubmed">22641927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winocur G., Berman H., Nguyen M., et al.  Neurobiological mechanisms of chemotherapy-induced cognitive impairment in a transgenic model of breast cancer. 
Neuroscience
. 2018;369:51–65. doi: 10.1016/j.neuroscience.2017.10.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2017.10.048</ArticleId>
            <ArticleId IdType="pubmed">29113931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Song W., Tong Y., et al.  Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-κB axis. 
Journal of Neuroinflammation
. 2021;18(1):p. 1. doi: 10.1186/s12974-020-02040-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-020-02040-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKenzie B. A., Dixit V. M., Power C. Fiery cell death: pyroptosis in the central nervous system. 
Trends in Neurosciences
. 2020;43(1):55–73. doi: 10.1016/j.tins.2019.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2019.11.005</ArticleId>
            <ArticleId IdType="pubmed">31843293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Peng H., Wu J., Xu Y. Brain natriuretic peptide-regulated expression of inflammatory cytokines in lipopolysaccharide (LPS)-activated macrophages via NF-κB and mitogen activated protein kinase (MAPK) pathways. 
Medical Science Monitor
. 2018;24:3119–3126. doi: 10.12659/msm.905580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/msm.905580</ArticleId>
            <ArticleId IdType="pmc">PMC5973487</ArticleId>
            <ArticleId IdType="pubmed">29754152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai W., Wang X., Teng H., Li C., Wang B., Wang J. Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats. 
International Immunopharmacology
. 2019;66:215–223. doi: 10.1016/j.intimp.2018.11.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.11.029</ArticleId>
            <ArticleId IdType="pubmed">30472522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques-Rocha J. L., Samblas M., Milagro F. I., Bressan J., Martínez J. A., Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. 
FASEB Journal
. 2015;29(9):3595–3611. doi: 10.1096/fj.14-260323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.14-260323</ArticleId>
            <ArticleId IdType="pubmed">26065857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X., Lin Q. MiRNA-495-3p attenuates TNF-α induced apoptosis and inflammation in human nucleus pulposus cells by targeting IL5RA. 
Inflammation
. 2020;43(5):1797–1805. doi: 10.1007/s10753-020-01254-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-020-01254-5</ArticleId>
            <ArticleId IdType="pubmed">32445070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue Z., Xi Q., Liu H., et al.  miR-21 promotes NLRP3 inflammasome activation to mediate pyroptosis and endotoxic shock. 
Cell Death &amp; Disease
. 2019;10(6):p. 461. doi: 10.1038/s41419-019-1713-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-019-1713-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Ge X., Yu J., et al.  Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowthviatheir transfer into neurons. 
FASEB Journal
. 2018;32(1):512–528. doi: 10.1096/fj.201700673r.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.201700673r</ArticleId>
            <ArticleId IdType="pubmed">28935818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan G., Li Y., Zhan L., et al.  Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5. 
American journal of cancer research
. 2019;9(3):585–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6448066</ArticleId>
            <ArticleId IdType="pubmed">30949412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao W., Yang H. MicroRNA-124-3p attenuates severe community-acquired pneumonia progression in macrophages by targeting tumor necrosis factor receptor-associated factor 6. 
International Journal of Molecular Medicine
. 2019;43(2):1003–1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30535475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You Y., Wang R., Shao N., Zhi F., Yang Y. Luteolin suppresses tumor proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. 
OncoTargets and Therapy
. 2019;12:2383–2396. doi: 10.2147/ott.s191158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/ott.s191158</ArticleId>
            <ArticleId IdType="pmc">PMC6445239</ArticleId>
            <ArticleId IdType="pubmed">30992674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao G., Ge R., Li Y., Liu S. Luteolin exhibits anti-breast cancer property through up-regulating miR-203. 
Artificial Cells, Nanomedicine, and Biotechnology
. 2019;47(1):3265–3271. doi: 10.1080/21691401.2019.1646749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21691401.2019.1646749</ArticleId>
            <ArticleId IdType="pubmed">31368817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu L.-H., Bi W., Qi R.-B., et al.  Luteolin reduces primary hippocampal neurons death induced by neuroinflammation. 
Neurological Research
. 2011;33(9):927–934. doi: 10.1179/1743132811y.0000000023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/1743132811y.0000000023</ArticleId>
            <ArticleId IdType="pubmed">22080993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L.-F., Chiu S.-P., Wu M.-J., Chen P.-Y., Yen J.-H. Luteolin induces microRNA-132 expression and modulates neurite outgrowth in PC12 cells. 
PLoS One
. 2012;7(8) doi: 10.1371/journal.pone.0043304.e43304</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0043304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishisaka M., Kakefuda K., Yamauchi M., et al.  Luteolin shows an antidepressant-like effect via suppressing endoplasmic reticulum stress. 
Biological and Pharmaceutical Bulletin
. 2011;34(9):1481–1486. doi: 10.1248/bpb.34.1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1248/bpb.34.1481</ArticleId>
            <ArticleId IdType="pubmed">21881237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J., Li G., Xu H., Wang Y., Shi M. Baicalin ameliorates chronic mild stress-induced depression-like behaviors in mice and attenuates inflammatory cytokines and oxidative stress. 
Brazilian journal of medical and biological research
. 2019;52(7) doi: 10.1590/1414-431X20198434.e8434</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/1414-431X20198434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourin M., Hascoët M., Colombel M. C., Coutts R. T., Baker G. B. Clonidine potentiates the effects of tranylcypromine, phenelzine and two analogues in the forced swimming test in mice. 
Journal of Psychiatry &amp; Neuroscience
. 2002;27(3):178–185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC161647</ArticleId>
            <ArticleId IdType="pubmed">12066447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Zhang X., Wang F., et al.  MicroRNA-21 lowers blood pressure in spontaneous hypertensive rats by upregulating mitochondrial translation. 
Circulation
. 2016;134(10):734–751. doi: 10.1161/circulationaha.116.023926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/circulationaha.116.023926</ArticleId>
            <ArticleId IdType="pmc">PMC5515592</ArticleId>
            <ArticleId IdType="pubmed">27542393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J., Feng L., Zhang G. Mitochondrial damage in hippocampal neurons of rats with epileptic protein expression of fas and caspase-3. 
Experimental and Therapeutic Medicine
. 2018;16(3):2483–2489. doi: 10.3892/etm.2018.6439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2018.6439</ArticleId>
            <ArticleId IdType="pmc">PMC6122536</ArticleId>
            <ArticleId IdType="pubmed">30210599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cvetković J., Nenadović M. Depression in breast cancer patients. 
Psychiatry Research
. 2016;240:343–347. doi: 10.1016/j.psychres.2016.04.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psychres.2016.04.048</ArticleId>
            <ArticleId IdType="pubmed">27138829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carreira H., Williams R., Müller M., Harewood R., Stanway S., Bhaskaran K. Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review. 
Journal of the National Cancer Institute
. 2018;110(12):1311–1327. doi: 10.1093/jnci/djy177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djy177</ArticleId>
            <ArticleId IdType="pmc">PMC6292797</ArticleId>
            <ArticleId IdType="pubmed">30403799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David D. J., Samuels B. A., Rainer Q., et al.  Neurogenesis-dependent and independent effects of fluoxetine in an animal model of anxiety/depression. 
Neuron
. 2009;62(4):479–493. doi: 10.1016/j.neuron.2009.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2009.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC2759281</ArticleId>
            <ArticleId IdType="pubmed">19477151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabavi S. F., Braidy N., Gortzi O., et al.  Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. 
Brain Research Bulletin
. 2015;119:1–11. doi: 10.1016/j.brainresbull.2015.09.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2015.09.002</ArticleId>
            <ArticleId IdType="pubmed">26361743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y., Shi R., Wang X., Shen H.-M. Luteolin, a flavonoid with potential for cancer prevention and therapy. 
Current Cancer Drug Targets
. 2008;8(7):634–646. doi: 10.2174/156800908786241050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/156800908786241050</ArticleId>
            <ArticleId IdType="pmc">PMC2615542</ArticleId>
            <ArticleId IdType="pubmed">18991571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed S., Khan H., Fratantonio D., et al.  Apoptosis induced by luteolin in breast cancer: mechanistic and therapeutic perspectives. 
Phytomedicine
. 2019;59 doi: 10.1016/j.phymed.2019.152883.152883</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phymed.2019.152883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crupi R., Paterniti I., Ahmad A., Campolo M., Esposito E., Cuzzocrea S. Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. 
CNS &amp; Neurological Disorders—Drug Targets
. 2013;12(7):989–1001. doi: 10.2174/18715273113129990084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/18715273113129990084</ArticleId>
            <ArticleId IdType="pubmed">23844686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fricker M., Tolkovsky A. M., Borutaite V., Coleman M., Brown G. C. Neuronal cell death. 
Physiological Reviews
. 2018;98(2):813–880. doi: 10.1152/physrev.00011.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00011.2017</ArticleId>
            <ArticleId IdType="pmc">PMC5966715</ArticleId>
            <ArticleId IdType="pubmed">29488822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart M. K., Cookson B. T. Evasion and interference: intracellular pathogens modulate caspase-dependent inflammatory responses. 
Nature Reviews Microbiology
. 2016;14(6):346–359. doi: 10.1038/nrmicro.2016.50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro.2016.50</ArticleId>
            <ArticleId IdType="pubmed">27174147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel M. N., Carroll R. G., Galván-Peña S., et al.  Inflammasome priming in sterile inflammatory disease. 
Trends in Molecular Medicine
. 2017;23(2):165–180. doi: 10.1016/j.molmed.2016.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2016.12.007</ArticleId>
            <ArticleId IdType="pubmed">28109721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin Z., Wang P.-Y., Su D.-F., Liu X. miRNA-124 in immune system and immune disorders. 
Frontiers in Immunology
. 2016;7:p. 406. doi: 10.3389/fimmu.2016.00406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2016.00406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang Y.-P., Liu Q., Xu G.-H., et al.  The lncRNA ROR/miR-124-3p/TRAF6 axis regulated the ischaemia reperfusion injury-induced inflammatory response in human cardiac myocytes. 
Journal of Bioenergetics and Biomembranes
. 2019;51(6):381–392. doi: 10.1007/s10863-019-09812-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10863-019-09812-9</ArticleId>
            <ArticleId IdType="pubmed">31768721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang Y., Hong X. miR-124-3p inhibits microglial secondary inflammation after basal ganglia hemorrhage by targeting TRAF6 and repressing the activation of NLRP3 inflammasome. 
Frontiers in Neurology
. 2021;12 doi: 10.3389/fneur.2021.653321.653321</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.653321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing Y., Yao X., Li H., et al.  Cutting edge: TRAF6 mediates TLR/IL-1R signaling-induced nontranscriptional priming of the NLRP3 inflammasome. 
Journal of Immunology
. 2017;199(5):1561–1566. doi: 10.4049/jimmunol.1700175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1700175</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
